GSK announced on December 11 that the European Commission has approved Dostarlimab (Jemperli) in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H).


